江西同和药业股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 本人作为江西同和药业股份有限公司（以下简称"公司"）的独 立董事，在任职期间严格按照《公司法》、《证券法》、《上市公司 治理准则》、《上市公司独立董事管理办法》和《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、 法规，以及《公司章程》、《独立董事制度》等规定，在 2024 年度 工作中，诚实、勤勉、独立的履行职责，积极出席相关会议，认真审 议董事会各项议案，对公司重大事项发表了独立意见，充分发挥了独 立董事及各专业委员会委员的作用，切实维护了公司和股东特别是中 小股东的利益，较好的发挥了独立董事的独立性和专业性作用。根据 中国证监会发布的《上市公司独立董事管理办法》和深圳证券交易所 发布的《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》有关要求，现将 2024 年度本人任职期间履行独立 董事职责情况报告如下： 一、 出席会议情况： 2024年度，本着勤勉尽责的态度，本人积极参加公司召开的股东 大会、董事会，认真审阅会议材料，积极参与各议题的讨论并提出合 理建议，以谨 ...

Financial Performance - The company's revenue for Q1 2025 was ¥186,897,547.53, representing a decrease of 9.47% compared to ¥206,454,983.02 in the same period last year[5] - Net profit attributable to shareholders was ¥20,781,376.97, down 52.30% from ¥43,562,751.14 year-on-year[5] - Basic and diluted earnings per share decreased by 52.27% to ¥0.0495 from ¥0.1037 in the same period last year[5] - The operating profit for the current period is CNY 22,045,134.74, down from CNY 49,031,953.90, reflecting a decline of 55.1%[23] - The total comprehensive income attributable to the parent company is CNY 20,781,376.97, down from CNY 43,562,751.14 in the previous period[23] Cash Flow - The net cash flow from operating activities increased by 19.91% to ¥35,664,255.22, compared to ¥29,743,589.13 in the previous year[11] - Cash flow from operating activities generated a net amount of CNY 35,664,255.22, an increase of 19.7% from CNY 29,743,589.13 in the previous period[25] - The net cash flow from investing activities increased by 110.82% to ¥16,089,848.66, compared to a negative cash flow of ¥148,676,249.14 in the previous year[11] - Cash flow from investing activities yielded a net inflow of CNY 16,089,848.66, compared to a net outflow of CNY 148,676,249.14 in the previous period[25] - Cash flow from financing activities resulted in a net inflow of CNY 78,708,229.72, up from CNY 150,196,833.20 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,421,287,186.43, an increase of 3.06% from ¥3,319,551,672.71 at the end of the previous year[5] - Total liabilities increased to ¥1,091,757,923.63 from ¥1,010,803,786.88, reflecting an increase of 8.0%[20] - The company's cash and cash equivalents increased to ¥306,214,227.30 from ¥176,384,468.01, representing a growth of 73.5%[19] - Total cash and cash equivalents at the end of the period amounted to CNY 296,214,227.30, down from CNY 525,619,976.92 in the previous period[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,278[13] - The largest shareholder, Pang Zhengwei, holds 14.71% of shares, totaling 62,027,337 shares, with 46,520,503 shares under pledge[13] - The second largest shareholder, Fenglong Industrial Co., Ltd., holds 13.17% of shares, totaling 55,511,352 shares[13] - The top ten shareholders collectively hold significant stakes, with the largest three shareholders accounting for 29.58% of total shares[13] Research and Development - Research and development expenses rose by 37.39% to ¥14,140,941.15, primarily due to increased labor costs and material consumption[10] - Research and development expenses rose significantly to ¥14,140,941.15, compared to ¥10,292,403.05 in the previous period, reflecting a 37.4% increase[22] - The company is currently undergoing internal renovations for the quality inspection and research and development building[17] Operational Insights - Total operating revenue for the current period is ¥186,897,547.53, a decrease of 9.4% from ¥206,454,983.02 in the previous period[22] - Total operating costs increased to ¥161,677,017.83, up 7.0% from ¥150,662,133.88 in the previous period[22] - The company's net profit margin is under pressure due to rising costs, with operating costs outpacing revenue growth[22] - The company has maintained a stable equity position, with total equity increasing to ¥2,329,529,262.80 from ¥2,308,747,885.83, a growth of 0.9%[21] Future Plans - The company has completed the main equipment procurement for the expansion project in the second factory area, with installation underway[17] - The company plans to implement new, modified, and expanded projects in the second factory area, which have been approved by the shareholders[17] - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[22] Stock Information - The total number of restricted shares at the beginning of the period was 57,109,218, with 2,986,962 shares released during the period[16] - The number of unrestricted shares held by the top ten unrestricted shareholders totals 55,511,352 shares[14] - The company has a stock incentive plan with a vesting period of 12, 24, and 36 months for certain shares[16] Taxation - The company reported a significant decrease in income tax expenses by 76.61%, amounting to ¥1,263,808.79 compared to ¥5,402,452.76 in the same period last year[10] - The company experienced a 164.80% increase in taxes and surcharges, amounting to ¥2,274,797.03, primarily due to an increase in value-added tax surcharges[10] Audit Status - The company has not yet audited the first quarter report for the current year[27]

Financial Performance - The company reported a total revenue of 1.2 billion yuan for the fiscal year 2024, representing a year-on-year growth of 15%[15]. - The company's operating revenue for 2024 reached ¥758,890,499.03, representing a 5.09% increase compared to ¥722,138,705.43 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥106,584,102.17, a slight increase of 0.57% from ¥105,983,257.15 in 2023[20]. - The company achieved a sales revenue of 758.89 million yuan in the reporting period, representing a year-on-year growth of 5.09%[64]. - The external sales revenue reached 614.02 million yuan, an increase of 6.76% compared to the same period last year[64]. - The company reported a significant increase in revenue, achieving a year-over-year growth of 25% in Q1 2024, totaling 1.5 billion RMB[130]. - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting revenues between $900 million and $950 million[126]. - The company reported a gross margin of 45%, indicating strong operational efficiency[130]. Research and Development - The company is investing 50 million yuan in R&D for new pharmaceutical products in 2024[15]. - The average R&D investment over the past three years accounts for 8.34% of sales, indicating a strong commitment to innovation and technology development[34]. - The R&D team consists of over 500 professionals, ensuring a robust pipeline of new products and technologies[55]. - Research and development investment amounted to 59.45 million yuan, accounting for 7.83% of the current operating revenue, maintaining a high investment level[64]. - The company is currently in the verification phase for multiple R&D projects aimed at enhancing product competitiveness and market presence[80]. - The company is investing heavily in R&D, with a budget increase of 30% for new technology development in 2024[130]. - The company has completed 18 technology development and process optimization projects during the reporting period, with 12 APIs and 8 intermediates undergoing pilot and trial production[68]. Market Expansion - The company aims to expand its market presence in Southeast Asia, targeting a 20% increase in sales in that region by 2025[15]. - The company is actively expanding into domestic markets, having submitted multiple projects for approval with several large and medium-sized pharmaceutical companies[34]. - The company plans to maintain a balance between entering high-end markets for higher sales prices and retaining competitiveness in low-end markets[106]. - The company will prioritize international markets for product sales while also investing more resources to expand its domestic market presence[107]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of the fiscal year[126]. - Market expansion plans include entering two new regions, aiming for a 10% market share in each by the end of 2024[130]. Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and management team, ensuring a coordinated and balanced mechanism among these entities[136]. - The company has appointed three independent directors to enhance the objectivity and fairness of board decisions[136]. - The company has a complete set of governance regulations, including articles of association and rules for shareholders' meetings, board meetings, and supervisory meetings[136]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[134]. - The company is committed to improving its internal control systems to enhance governance levels[136]. - The company has established a complete and independent financial institution, with a sufficient number of dedicated financial accounting personnel and an independent accounting system and financial management system[146]. Environmental and Safety Management - The company emphasizes environmental protection and has advanced wastewater and air treatment capabilities, with a wastewater treatment capacity of 1,500 tons per day in one plant[61]. - The company has established a comprehensive safety management system, including a safety production committee led by the general manager, to ensure compliance with safety regulations[120]. - The company is continuously investing in environmental protection facilities and optimizing production processes to meet increasingly stringent environmental standards[120]. Employee Management and Compensation - The company emphasizes enhancing employee performance through a competitive compensation policy, including salaries, benefits, and performance-based bonuses[177]. - The training program aims to improve employee skills and competencies, focusing on regular training, professional skills, and management knowledge[178]. - The total pre-tax remuneration for the company's directors, supervisors, and senior management during the reporting period amounted to 6.8491 million yuan[164]. - The highest remuneration was received by the Chairman and General Manager, Mr. Pang Zhengwei, totaling 928,100 yuan[164]. - The company has a total of 1,418 employees, with a professional composition including 717 production personnel, 30 sales personnel, 541 technical personnel, 9 financial personnel, and 121 administrative personnel[175]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[15]. - The company plans to invest $100 million in marketing to support new product launches and market expansion efforts[126]. - The company aims to conduct timely mergers and acquisitions to extend its industry chain and enhance its scale and strength[116]. - The company has completed CDE approvals for several products, including Venlafaxine Hydrochloride and Celecoxib, positioning itself as a major supplier in the domestic market[41]. Risks and Challenges - The company has identified key risks including regulatory changes and market competition, which may impact future performance[5]. - The company faces risks related to the loss of core technical personnel, which could impact its competitive advantage and operational stability[123]. - The company's export revenue constitutes a significant portion of its total revenue, making it vulnerable to exchange rate fluctuations, particularly with the appreciation of the RMB against the USD[124].

2025 年 4 月 23 日 1/ 1 江西同和药业股份有限公司 董事会关于独立董事独立性情况的专项意见 江西同和药业股份有限公司（以下简称"公司"）董事会根据《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》等要求，并结合在任独立董 事出具的《独立董事独立性自查报告》，认为公司在任独立董事未在 公司担任除独立董事以外的任何职务，也未在公司主要股东公司担任 任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍 其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符 合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等法律法规及《公司 章程》中关于独立董事的任职资格及独立性的要求。 江西同和药业股份有限公司董事会 ...

江西同和药业股份有限公司 江西同和药业股份有限公司 一、2024 年度监事会主要工作 报告期内，公司监事会依法履行职责，认真进行了监督和检查。 （一）对公司经营活动的监督 监事会成员列席了 2024 年公司召开的历次董事会和股东大会会 议，听取了公司生产、经营、投资、财务等方面的工作报告，对公司 经营管理中重大决策的程序及实施情况进行了监督。在公司管理层执 行股东大会决议、董事会决议以及生产经营计划、重大投资方案、财 务决算方案等方面，监事会适时审议有关报告，了解公司经营管理活 动的具体情况，并对此提出相应的意见和建议。 （二）对财务活动的监督 公司监事会把检查公司财务状况作为监事会的工作重点，对完善 内控制度进行了监督，并通过查阅公司财务账簿及其他会计资料，及 1/ 7 2024 年度监事会工作报告 2024 年，江西同和药业股份有限公司（以下简称"公司"）监 事会严格依照《公司法》、《证券法》、《创业板股票上市规则》、 《上市公司自律监管指引第 2 号——创业板上市公司规范运作》及 《公司章程》、《监事会议事规则》等有关法律法规及规章制度的要 求，围绕公司年度生产经营目标切实开展了各项工作。公司全体监事 ...

证券代码：300636 证券简称：同和药业 公告编号：2025-022 江西同和药业股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 为提高资金使用效率，合理利用暂时闲置募集资金，增加公司收 益，江西同和药业股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开第四届董事会第四次会议，审议通过了《关于使用暂时闲 置募集资金进行现金管理的议案》，公司拟使用不超过人民币 1 亿元 的暂时闲置募集资金适时进行现金管理，投资决议有效期限自公司股 东大会审议通过之日至 2025 年年度股东大会召开之日有效，在授权 额度内滚动使用，在额度范围内公司董事会授权董事长行使该项投资 决策并签署相关合同文件。以上议案尚需提交股东大会审议。详细情 况公告如下： 一、募集资金基本情况 根据公司 2022 年 7 月 1 日召开的第三届董事会第十次会议审议 通过的《关于公司符合向特定对象发行 A 股股票条件的议案》《关于 公司 2022 年度向特定对象发行 A 股股票方案的议案》及与本次发行 相关的其他议案、202 ...

证券代码：300636 证券简称：同和药业 公告编号：2025-015 江西同和药业股份有限公司 关于 2024 年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于2025年4月 23日召开第四届董事会第四次会议和第四届监事会第四次会议，审议 通过了《关于计提资产减值准备的议案》。现将相关事项公告如下： 1/ 5 | 资产减值损失（损失以"-"号填列） | 存货跌价损失 | -26,567,161.93 | | --- | --- | --- | | | 合计 | -27,880,076.71 | 一、 计提信用减值准备和资产减值准备情况概述 1、 本次计提信用减值准备和资产减值准备的原因 为真实、公允、准确地反映公司截至 2024年12月31日的资产和 财务状况，公司根据《企业会计准则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》及公司会计政策 的相关规定，对合并范围内截至2024年末的各类资产进行全面清查， 并进行充分的评估和分析。经资产减值测试，公司认 ...

江西同和药业股份有限公司 非经营性资金占用及其他关联资 金往来情况专项报告的鉴证报告 二〇二四年度 关于江西同和药业股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZA10663 号 江西同和药业股份有限公司全体股东： 我们审计了江西同和药业股份有限公司(以下简称"同和药 业")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流量 表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 04 月 23 日出具了报告号为信会师报字[2025]第 ZA10661 号的无 保留意见审计报告。 同和药业管理层根据中国证券监督管理委员会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公 告〔2022〕26 号）和《深圳证券交易所创业板上市公司自律监管指南 第 1 号——业务办理》的相关规定编制了后附的 2024 年度非经营性 资金占用及其他关联资金往来情况汇总表（以下简称"汇总表"）。 编制汇总表并确保其真实、准确、完整是同和药业管理层 ...

同和药业（300636）公告，公司近日收到韩国食品药品安全部颁发的美阿沙坦钾药品注册证书。生产商 名称为江西同和药业股份有限公司，生产商地址为江西省奉新高新技术产业园区，认证范围为美阿沙坦 钾原料药，证书编号为2025-A1-0844，签发日期为2025.04.14。美阿沙坦钾适用于治疗成人原发性高血 压。公司美阿沙坦钾产品获得韩国药品注册证书，标志着公司美阿沙坦钾原料药获得了韩国市场的准入 资格，将对公司进一步扩大国际市场业务起到积极作用。 ...

江西同和药业股份有限公司 关于公司获得韩国药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：300636 证券简称：同和药业 公告编号：2025-009 签发日期：2025.04.14 美阿沙坦钾适用于治疗成人原发性高血压。 公司美阿沙坦钾产品获得韩国药品注册证书，标志着公司美阿沙 坦钾原料药获得了韩国市场的准入资格，将对公司进一步扩大国际市 场业务起到积极作用。由于医药行业的特点，相关产品在国际市场的 销售情况易受到市场环境变化、汇率波动等因素影响，敬请广大投资 者谨慎决策，注意防范投资风险。 特此公告。 江西同和药业股份有限公司董事会 二〇二五年四月十五日 江西同和药业股份有限公司（以下简称"公司"）于近日收到韩 国食品药品安全部（MFDS）颁发的美阿沙坦钾药品注册证书，相关信 息如下： 生产商名称：江西同和药业股份有限公司 生产商地址：江西省奉新高新技术产业园区 认证范围：美阿沙坦钾原料药 证书编号：2025-A1-0844 1/ 1 ...